FindTrial
Sign In

Hepatitis B infection rates and immunogenicity of hepatitis B vaccine in Chinese diabetic population

Study for Optimized Immunization Strategy of Hepatitis B Vaccine in High-risk Population and Community Population of Chinese Adults

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800020190
Enrollment
Unknown
Registered
2018-12-19
Start date
2019-01-01
Completion date
Unknown
Last updated
2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis B virus infection

Interventions

Group Diabetes 1:20µg CHO recombinant hepatitis B vaccine
Group Diabetes 2:20µg yeast recombinant hepatitis B vaccine
Group Diabetes 3:60µg hepatitis B vaccine
Control Group:20µg yeast recombinant hepatitis B vaccine

Sponsors

School of Public Health, Peking University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
27 Years to 59 Years

Inclusion criteria

Inclusion criteria: (1) Aged 27-59 years old; (2) Patients in the endocrinology department of the target hospital for treatment or hospitalization; (3) Clearly diagnosed as diabetes; (4) Persons who have lived in the province for a long time; (5) Informed consent and voluntary participation in the study.

Exclusion criteria

Exclusion criteria: (1) HBV infection due to mother-to-child transmission; (2) HBV infection occured before the diagnosis of diabetes; (3) Patients with missing case data and memory impairment; (4) Refusing to participate in the survey.

Design outcomes

Primary

MeasureTime frame
HBsAg;HBsAb;HBcAb;—

Countries

China

Contacts

Public ContactFuqiang Cui

School of Public Health, Peking University

cuifuq@126.com+86 13718891696

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026